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background: Elevated cardiac filling pressures precede signs and symptoms that lead to decompensation, and implantable hemodynamic 
monitoring (IHM) devices allow home monitoring of this signal. The randomized portion of the CHAMPION trial demonstrated a significant reduction 
in heart failure hospitalizations (HFH) in patients managed with home pulmonary artery pressure (PAP) readings. All patients had a wireless PAP 
sensor implanted at the beginning of the randomized trial but only the treatment group was managed utilizing PAP. After the randomized portion of 
the trial, all patients were managed utilizing PAP (Open Access). We report the impact of the introduction of PAP information during the Open Access 
(OA) Period.
Methods: CHAMPION was a prospective, randomized, single-blind study that enrolled 550 patients with NYHA class III HF who were implanted 
with the IHM device and randomized to treatment (270) or control (280). During the Randomized Access (RA) Period (mean follow-up=18 months), 
physicians had access to PAP information for Treatment patients only. After the completion of RA, all patients entered the OA Period (mean follow-
up=13 months). During OA, physicians had new access to PAP in the Control group (Former Control, n=170). Access to PAP in the Treatment group 
(Former Treatment, n=177) remained unchanged. All hospitalizations were adjudicated by a blinded clinical events committee.
results: During OA, new physician access to PAP in the Former Control group resulted in a 48% reduction in HFH rates (0.36 vs. 0.68, HR 0.52, 
95% CI 0.40-0.69, p<0.0001). The low HFH rate in the Treatment group during RA was maintained in the Former Treatment group during the OA 
period (0.45 vs. 0.48, HR 0.93, 95% CI 0.70-1.22, p=0.5838). The magnitude of the change in HFH rate in the Control group was significantly 
greater than in the Treatment group (HR 0.56, 95% CI 0.38-0.83, p=0.0040).
conclusion: PAP monitoring resulted in significant reductions in HFH during OA in patients previously managed using standard tools only. New 
access to PAP monitoring resulted in a significant reduction in HFH even after adjustment for longitudinal confounders. These data confirm the 
effectiveness findings from the RA period.
